National Health Research Institute
National Health Research Institute
National Health Research Institute | Date: 2017-07-26
The present application provides a method of upregulating an expression of immumodulatory cells in vitro comprising treating the immumodulatory cells with IL-25 to increase an expression of PD-L1. The present application also provides a method for treatment of immune disorders by the aforementioned methods. The present application also provides a method to suppress an expression of immumodulatory cells comprising suppressing an expression of PD-L1. The immumodulatory cells can be human monocytes or hMSCs. The present application further provides a method for treatment of immune-evasive diseases by using the aforementioned method to suppress an expression of immumodulatory cells.
National Health Research Institute and Wu | Date: 2017-08-02
ABSTRACT The present invention relates a diagnostic method for inflammatory diseases, and the diagnostic kit used in the method. The diagnostic method of present invention comprises the use of a novel tryptophan metabolite, 5-methoxytryptophan (5-MTP), as a diagnostic biomarker of inflammation. The present invention specially provides a highly specific competitive ELISA to measure 5-MTP level in human serum for gauging occurrence and severity of inflammatory diseases, including sepsis and systemic lupus.
Chao and National Health Research Institute | Date: 2017-08-02
Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds.
National Health Research Institute | Date: 2017-01-30
Aminothiazole compounds of Formula (I) shown herein and pharmaceutical compositions containing one of such compounds.
National Health Research Institute | Date: 2016-05-19
A microfluidic dual-well device is disclosed. The device comprises: (a) a first substrate having a first end, a second end, and a culture microwell forming portion; (b) a plurality of culture microwells; (c) a second substrate having a first end, a second end, and a capture microwell forming portion, the two ends of the second substrate being respectively bounded to the two ends of the first substrate; (d) a plurality of capture microwells; (e) a microfluidic channel; (f) a microfluidic inlet port; and (g) a microfluidic outlet port; wherein the microfluidic channel is in fluidic connections with the culture microwells, the capture microwells, and the inlet and outlet ports. Methods of capturing and transferring a single cell or a single cell colony for culture, and method of transferring a target cell from a polydimethylsiloxane (PDMS) structure of culture microwells to a culture plate for culture are also disclosed.
Tseng, National Taiwan University, National Chiao Tung University and National Health Research Institute | Date: 2017-03-08
The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapydrug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.
National Health Research Institute and University of Minnesota | Date: 2016-07-12
Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method for treating an opioid receptor-associated condition using a compound of Formula (I) and a pharmaceutical composition containing the same.
National Health Research Institute and Chong | Date: 2017-06-21
The present application provides a composition and methods to enhance nerve regeneration utilizing at least one component of neural stem cells or IL12p40. The composition comprises neural stem cells and a neurotrophic factor, which is constructed by IL12p40 as at least one subunit. The methods to enhance nerve regeneration comprise providing a nerve regeneration composition comprising a neurotrophic factor containing IL12p40 as at least one subunit to a subject. The composition of the methods can further comprise neural stem cells.
Taipei Medical University, National Health Research Institute and Yen | Date: 2017-02-15
Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.
Adelman K.,National Health Research Institute
Nature reviews. Genetics | Year: 2012
Recent years have witnessed a sea change in our understanding of transcription regulation: whereas traditional models focused solely on the events that brought RNA polymerase II (Pol II) to a gene promoter to initiate RNA synthesis, emerging evidence points to the pausing of Pol II during early elongation as a widespread regulatory mechanism in higher eukaryotes. Current data indicate that pausing is particularly enriched at genes in signal-responsive pathways. Here the evidence for pausing of Pol II from recent high-throughput studies will be discussed, as well as the potential interconnected functions of promoter-proximally paused Pol II.